The U.S. Federal Trade Commission has approved the pending $43 billion merger between Medtronic and Covidien, according to regulatory filings.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Will Stryker bid on Smith & Nephew this week?: J&J demands $7.2 billion from Boston Scientific as trial begins; Will Orange County's medtech scene lose its juice without Allergan?; BD-CareFusion deal passes US anti-trust waiting period; Sources: Stryker weighs bid for Smith & Nephew
, Becton Dickinson & Co.
, Boston Scientific
, CareFusion Corp.
, Guidant Corp.
, Johnson & Johnson
, Smith & Nephew
, Valeant Pharmaceuticals
, Allergan Inc.
Covidien says it received a subpoena from the inspector general of the U.S. Health & Human Services Dept. over some of its peripheral vascular devices.
Covidien says it won 510(k) clearance from the FDA for its Fortrex PTA balloon catheter, designed both for maintaining blood vessel access for hemodialysis and for treating peripheral artery disease.
Speculation mounts again about a possible Stryker offer for Smith & Nephew now that a 6-month no-bid period has ended.
UPDATED Nov. 24 with analysis from Morgan Stanley.
Covidien says it won CE Mark approval in the European Union for home use of its Nellcor bedside SpO2 patient monitoring system.
Covidien (NYSE:COV) said it won CE Mark approval in the European Union for home use of its Nellcor bedside SpO2 patient monitoring system.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Report: Medtronic readies $10B bond flotation for Covidien deal; Medtech mergers stayed strong in Q3; Sources: Philips attracts private equity bids for lighting unit; Medtronic, Covidien set timetable for shareholders meetings; Report: Actavis may buy Allergan for at least $60 billion